Rocket Pharmaceuticals secured FDA approval for Kresladi, its gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1). The company said the approval makes Kresladi the first gene therapy commercially available for this ultra-rare immune disorder. For investors and biotech operators, the move underscores the continuing maturation of gene therapy into narrow indications where small patient populations can still support development and commercialization. It also highlights Rocket’s ability to translate platform development into a regulatory outcome. Details on labeling expansion and post-marketing requirements were not included in the provided material, but the approval positions the company to build clinical and payer experience for LAD-1 treatment pathways.